Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

Launched by NATIONAL CANCER INSTITUTE, NAPLES · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to screen for endometrial cancer, which is a type of cancer that affects the lining of the uterus. Researchers are testing a specific "metabolomic signature," a unique pattern of molecules in the body, to see if it can help tell the difference between benign (non-cancerous) growths and different types of cancerous growths. The goal is to improve early detection of endometrial carcinoma.

To participate in this study, you must be a woman aged between 50 and 80 who is post-menopausal and willing to sign consent to take part. Unfortunately, if you've had a hysterectomy, are on hormone replacement therapy, or are receiving immunosuppressive treatment, you would not be eligible. If you join the trial, you’ll help researchers learn more about this potential new screening method, which could ultimately lead to better outcomes for women facing this cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Female sex
• • 2. Age between 50 and 80 years
• • 3. Willingness to participate in the study and signing of the informed consent
• • 4. Clinical condition of post-menopause
• Exclusion Criteria:
• • 1. Previous hysterectomy
• • 2. Hormone replacement therapy
• • 3. Immunosuppressive therapy